Suma Shankar | University of California, Davis (original) (raw)

Papers by Suma Shankar

Research paper thumbnail of Identification of a Novel Genetic Locus for Familial Cavitary Optic Disc Anomalies

Investigative Ophthalmology & Visual Science, May 10, 2007

Research paper thumbnail of The phenotypic characteristics of the p.N215S Fabry disease genotype in male and female patients: a multi-center Fabry Registry study

Molecular Genetics and Metabolism, 2017

Research paper thumbnail of Eye findings in Fabry disease and correlation with disease severity

Molecular Genetics and Metabolism, Feb 1, 2016

Research paper thumbnail of Natural history of Fabry disease in male and female patients with the N215S genotype

Molecular Genetics and Metabolism, Feb 1, 2016

Research paper thumbnail of Atypical presentation of Angelman syndrome with intact expressive language due to low‐level mosaicism

Molecular Genetics & Genomic Medicine

Research paper thumbnail of Retinal dystrophies: A look beyond the eyes

American Journal of Ophthalmology Case Reports

Research paper thumbnail of The seventh international RASopathies symposium: Pathways to a cure—expanding knowledge, enhancing research, and therapeutic discovery

American Journal of Medical Genetics Part A, 2022

RASopathies are a group of genetic disorders that are caused by genes that affect the canonical R... more RASopathies are a group of genetic disorders that are caused by genes that affect the canonical Ras/mitogen‐activated protein kinase (MAPK) signaling pathway. Despite tremendous progress in understanding the molecular consequences of these genetic anomalies, little movement has been made in translating these findings to the clinic. This year, the seventh International RASopathies Symposium focused on expanding the research knowledge that we have gained over the years to enhance new discoveries in the field, ones that we hope can lead to effective therapeutic treatments. Indeed, for the first time, research efforts are finally being translated to the clinic, with compassionate use of Ras/MAPK pathway inhibitors for the treatment of RASopathies. This biannual meeting, organized by the RASopathies Network, brought together basic scientists, clinicians, clinician scientists, patients, advocates, and their families, as well as representatives from pharmaceutical companies and the Nationa...

Research paper thumbnail of Does the Complement Factor H (CFH) Tyr402His Polymorphism Affect the Retinal Phenotype of a Clinically Variable RDS Mutation

Investigative Ophthalmology & Visual Science, 2007

Research paper thumbnail of Retinal degeneration in mice and humans with neuronal ceroid lipofuscinosis type 8

Annals of translational medicine, 2021

Background Ceroid lipofuscinosis type 8 belongs to a heterogenous group of vision and life-threat... more Background Ceroid lipofuscinosis type 8 belongs to a heterogenous group of vision and life-threatening neurodegenerative diseases, neuronal ceroid lipofuscinosis (NCL). Effective therapy is limited to a single drug for treatment of ceroid lipofuscinosis type 2, necessitating animal disease models to facilitate further therapeutic development. Murine models are advantageous for therapeutic development due to easy genetic manipulation and rapid breeding, however appropriate genetic models need to be identified and characterized before being used for therapy testing. To date, murine models of ocular disease associated with ceroid lipofuscinosis type 8 have only been characterized in motor neuron degeneration mice. Methods Cln8-/- mice were produced by CRISPR/Cas9 genome editing through the International Mouse Phenotyping Consortium. Ophthalmic examination, optical coherence tomography, electroretinography, and ocular histology was performed on Cln8-/- mice and controls at 16 weeks of a...

Research paper thumbnail of Novel FRMD7 Mutation Is Associated With X-Linked Idiopathic Congenital Nystagmus in a Large Pedigree From Iowa

Investigative Ophthalmology & Visual Science, 2007

Research paper thumbnail of Long-term study of growth and development outcomes in patients with infantile-onset Pompe disease receiving alglucosidase alfa: Safety data update

Molecular Genetics and Metabolism, 2018

and demographic variables were used as predictors in this model. Optimal clustering and goodness-... more and demographic variables were used as predictors in this model. Optimal clustering and goodness-of-fit were assessed by BIC score. Clusters represented distinct phenotypic groups which aligned with GBA1 mutation and PD status. UPSIT was the best predictor of class status, as expected, providing proof of principle. FSS also predicted cluster well. This is the first use of LCCA and discriminant analysis to identify phenotypic profiles of GBA1 mutation carriers. These methods may help identify at-risk individuals likely to benefit from early therapeutic interventions.

Research paper thumbnail of Project Baby Bear: Rapid precision care incorporating rWGS in 5 California children’s hospitals demonstrates improved clinical outcomes and reduced costs of care

The American Journal of Human Genetics, 2021

Genetic disorders are a leading contributor to mortality in neonatal and pediatric intensive care... more Genetic disorders are a leading contributor to mortality in neonatal and pediatric intensive care units (ICUs). Rapid whole-genome sequencing (rWGS)-based rapid precision medicine (RPM) is an intervention that has demonstrated improved clinical outcomes and reduced costs of care. However, the feasibility of broad clinical deployment has not been established. The objective of this study was to implement RPM based on rWGS and evaluate the clinical and economic impact of this implementation as a first line diagnostic test in the California Medicaid (Medi-Cal) program. Project Baby Bear was a payor funded, prospective, real-world quality improvement project in the regional ICUs of five tertiary care children's hospitals. Participation was limited to acutely ill Medi-Cal beneficiaries who were admitted November 2018 to May 2020, were <1 year old and within one week of hospitalization, or had just developed an abnormal response to therapy. The whole cohort received RPM. There were two prespecified primary outcomes-changes in medical care reported by physicians and changes in the cost of care. The majority of infants were from underserved populations. Of 184 infants enrolled, 74 (40%) received a diagnosis by rWGS that explained their admission in a median time of 3 days. In 58 (32%) affected individuals, rWGS led to changes in medical care. Testing and precision medicine cost 1.7millionandledto1.7 million and led to 1.7millionandledto2.2-2.9 million cost savings. rWGS-based RPM had clinical utility and reduced net health care expenditures for infants in regional ICUs. rWGS should be considered early in ICU admission when the underlying etiology is unclear.

Research paper thumbnail of Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial

Molecular Genetics and Metabolism, 2019

Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year random... more Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial

Research paper thumbnail of First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and advances of new therapeutics

American Journal of Medical Genetics Part A, 2019

The neurofibromatoses, which include neurofibromatosis type I (NF1), neurofibromatosis type II (N... more The neurofibromatoses, which include neurofibromatosis type I (NF1), neurofibromatosis type II (NF2), and schwannomatosis, are a group of syndromes characterized by tumor growth in the nervous system. The RASopathies are a group of syndromes caused by germline mutations in genes that encode components of the RAS/mitogen‐activated protein kinase (MAPK) pathway. The RASopathies include NF1, Noonan syndrome, Noonan syndrome with multiple lentigines, Costello syndrome, cardio‐facio‐cutaneous syndrome, Legius syndrome, capillary malformation arterio‐venous malformation syndrome, and SYNGAP1 autism. Due to their common underlying pathogenetic etiology, all these syndromes have significant phenotypic overlap of which one common feature include a predisposition to tumors, which may be benign or malignant. Together as a group, they represent one of the most common multiple congenital anomaly syndromes estimating to affect approximately one in 1000 individuals worldwide. The subcontinent of I...

Research paper thumbnail of Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study

Molecular genetics & genomic medicine, Jan 12, 2018

The p.Asn215Ser or p.N215S GLA variant has been associated with late-onset cardiac variant of Fab... more The p.Asn215Ser or p.N215S GLA variant has been associated with late-onset cardiac variant of Fabry disease. To expand on the scarce phenotype data, we analyzed natural history data from 125 p.N215S patients (66 females, 59 males) enrolled in the Fabry Registry (NCT00196742) and compared it with data from 401 patients (237 females, 164 males) harboring mutations associated with classic Fabry disease. We evaluated interventricular septum thickness (IVST), left ventricular posterior wall thickness (LVPWT), estimated glomerular filtration rate and severe clinical events. In p.N215S males, mildly abnormal mean IVST and LVPWT values were observed in patients aged 25-34 years, and values gradually increased with advancing age. Mean values were similar to those of classic males. In p.N215S females, these abnormalities occurred primarily in patients aged 55-64 years. Severe clinical events in p.N215S patients were mainly cardiac (males 31%, females 8%) while renal and cerebrovascular events...

Research paper thumbnail of A randomized, phase 3B, open-label, parallel-group study of agalsidase beta in treatment-naive male pediatric patients with Fabry disease without severe symptoms (FIELD study): GL-3 clearance from kidney cells

Molecular Genetics and Metabolism, 2017

Research paper thumbnail of Response of patients with Fabry disease with the amenable GLA mutation p.N215S to treatment with migalastat

Molecular Genetics and Metabolism, 2017

Research paper thumbnail of Segregation analysis of a large LHON pedigree is consistent with the existence of a nuclear modifying gene

Research paper thumbnail of Linkage analysis of the X chromosome in a Brazilian family with Leber hereditary optic neuropathy (LHON)

Research paper thumbnail of Autosomal dominant retinitis pigmentosa: exclusion of known and mapped genes in three families

Research paper thumbnail of Identification of a Novel Genetic Locus for Familial Cavitary Optic Disc Anomalies

Investigative Ophthalmology & Visual Science, May 10, 2007

Research paper thumbnail of The phenotypic characteristics of the p.N215S Fabry disease genotype in male and female patients: a multi-center Fabry Registry study

Molecular Genetics and Metabolism, 2017

Research paper thumbnail of Eye findings in Fabry disease and correlation with disease severity

Molecular Genetics and Metabolism, Feb 1, 2016

Research paper thumbnail of Natural history of Fabry disease in male and female patients with the N215S genotype

Molecular Genetics and Metabolism, Feb 1, 2016

Research paper thumbnail of Atypical presentation of Angelman syndrome with intact expressive language due to low‐level mosaicism

Molecular Genetics & Genomic Medicine

Research paper thumbnail of Retinal dystrophies: A look beyond the eyes

American Journal of Ophthalmology Case Reports

Research paper thumbnail of The seventh international RASopathies symposium: Pathways to a cure—expanding knowledge, enhancing research, and therapeutic discovery

American Journal of Medical Genetics Part A, 2022

RASopathies are a group of genetic disorders that are caused by genes that affect the canonical R... more RASopathies are a group of genetic disorders that are caused by genes that affect the canonical Ras/mitogen‐activated protein kinase (MAPK) signaling pathway. Despite tremendous progress in understanding the molecular consequences of these genetic anomalies, little movement has been made in translating these findings to the clinic. This year, the seventh International RASopathies Symposium focused on expanding the research knowledge that we have gained over the years to enhance new discoveries in the field, ones that we hope can lead to effective therapeutic treatments. Indeed, for the first time, research efforts are finally being translated to the clinic, with compassionate use of Ras/MAPK pathway inhibitors for the treatment of RASopathies. This biannual meeting, organized by the RASopathies Network, brought together basic scientists, clinicians, clinician scientists, patients, advocates, and their families, as well as representatives from pharmaceutical companies and the Nationa...

Research paper thumbnail of Does the Complement Factor H (CFH) Tyr402His Polymorphism Affect the Retinal Phenotype of a Clinically Variable RDS Mutation

Investigative Ophthalmology & Visual Science, 2007

Research paper thumbnail of Retinal degeneration in mice and humans with neuronal ceroid lipofuscinosis type 8

Annals of translational medicine, 2021

Background Ceroid lipofuscinosis type 8 belongs to a heterogenous group of vision and life-threat... more Background Ceroid lipofuscinosis type 8 belongs to a heterogenous group of vision and life-threatening neurodegenerative diseases, neuronal ceroid lipofuscinosis (NCL). Effective therapy is limited to a single drug for treatment of ceroid lipofuscinosis type 2, necessitating animal disease models to facilitate further therapeutic development. Murine models are advantageous for therapeutic development due to easy genetic manipulation and rapid breeding, however appropriate genetic models need to be identified and characterized before being used for therapy testing. To date, murine models of ocular disease associated with ceroid lipofuscinosis type 8 have only been characterized in motor neuron degeneration mice. Methods Cln8-/- mice were produced by CRISPR/Cas9 genome editing through the International Mouse Phenotyping Consortium. Ophthalmic examination, optical coherence tomography, electroretinography, and ocular histology was performed on Cln8-/- mice and controls at 16 weeks of a...

Research paper thumbnail of Novel FRMD7 Mutation Is Associated With X-Linked Idiopathic Congenital Nystagmus in a Large Pedigree From Iowa

Investigative Ophthalmology & Visual Science, 2007

Research paper thumbnail of Long-term study of growth and development outcomes in patients with infantile-onset Pompe disease receiving alglucosidase alfa: Safety data update

Molecular Genetics and Metabolism, 2018

and demographic variables were used as predictors in this model. Optimal clustering and goodness-... more and demographic variables were used as predictors in this model. Optimal clustering and goodness-of-fit were assessed by BIC score. Clusters represented distinct phenotypic groups which aligned with GBA1 mutation and PD status. UPSIT was the best predictor of class status, as expected, providing proof of principle. FSS also predicted cluster well. This is the first use of LCCA and discriminant analysis to identify phenotypic profiles of GBA1 mutation carriers. These methods may help identify at-risk individuals likely to benefit from early therapeutic interventions.

Research paper thumbnail of Project Baby Bear: Rapid precision care incorporating rWGS in 5 California children’s hospitals demonstrates improved clinical outcomes and reduced costs of care

The American Journal of Human Genetics, 2021

Genetic disorders are a leading contributor to mortality in neonatal and pediatric intensive care... more Genetic disorders are a leading contributor to mortality in neonatal and pediatric intensive care units (ICUs). Rapid whole-genome sequencing (rWGS)-based rapid precision medicine (RPM) is an intervention that has demonstrated improved clinical outcomes and reduced costs of care. However, the feasibility of broad clinical deployment has not been established. The objective of this study was to implement RPM based on rWGS and evaluate the clinical and economic impact of this implementation as a first line diagnostic test in the California Medicaid (Medi-Cal) program. Project Baby Bear was a payor funded, prospective, real-world quality improvement project in the regional ICUs of five tertiary care children's hospitals. Participation was limited to acutely ill Medi-Cal beneficiaries who were admitted November 2018 to May 2020, were <1 year old and within one week of hospitalization, or had just developed an abnormal response to therapy. The whole cohort received RPM. There were two prespecified primary outcomes-changes in medical care reported by physicians and changes in the cost of care. The majority of infants were from underserved populations. Of 184 infants enrolled, 74 (40%) received a diagnosis by rWGS that explained their admission in a median time of 3 days. In 58 (32%) affected individuals, rWGS led to changes in medical care. Testing and precision medicine cost 1.7millionandledto1.7 million and led to 1.7millionandledto2.2-2.9 million cost savings. rWGS-based RPM had clinical utility and reduced net health care expenditures for infants in regional ICUs. rWGS should be considered early in ICU admission when the underlying etiology is unclear.

Research paper thumbnail of Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial

Molecular Genetics and Metabolism, 2019

Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year random... more Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial

Research paper thumbnail of First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and advances of new therapeutics

American Journal of Medical Genetics Part A, 2019

The neurofibromatoses, which include neurofibromatosis type I (NF1), neurofibromatosis type II (N... more The neurofibromatoses, which include neurofibromatosis type I (NF1), neurofibromatosis type II (NF2), and schwannomatosis, are a group of syndromes characterized by tumor growth in the nervous system. The RASopathies are a group of syndromes caused by germline mutations in genes that encode components of the RAS/mitogen‐activated protein kinase (MAPK) pathway. The RASopathies include NF1, Noonan syndrome, Noonan syndrome with multiple lentigines, Costello syndrome, cardio‐facio‐cutaneous syndrome, Legius syndrome, capillary malformation arterio‐venous malformation syndrome, and SYNGAP1 autism. Due to their common underlying pathogenetic etiology, all these syndromes have significant phenotypic overlap of which one common feature include a predisposition to tumors, which may be benign or malignant. Together as a group, they represent one of the most common multiple congenital anomaly syndromes estimating to affect approximately one in 1000 individuals worldwide. The subcontinent of I...

Research paper thumbnail of Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study

Molecular genetics & genomic medicine, Jan 12, 2018

The p.Asn215Ser or p.N215S GLA variant has been associated with late-onset cardiac variant of Fab... more The p.Asn215Ser or p.N215S GLA variant has been associated with late-onset cardiac variant of Fabry disease. To expand on the scarce phenotype data, we analyzed natural history data from 125 p.N215S patients (66 females, 59 males) enrolled in the Fabry Registry (NCT00196742) and compared it with data from 401 patients (237 females, 164 males) harboring mutations associated with classic Fabry disease. We evaluated interventricular septum thickness (IVST), left ventricular posterior wall thickness (LVPWT), estimated glomerular filtration rate and severe clinical events. In p.N215S males, mildly abnormal mean IVST and LVPWT values were observed in patients aged 25-34 years, and values gradually increased with advancing age. Mean values were similar to those of classic males. In p.N215S females, these abnormalities occurred primarily in patients aged 55-64 years. Severe clinical events in p.N215S patients were mainly cardiac (males 31%, females 8%) while renal and cerebrovascular events...

Research paper thumbnail of A randomized, phase 3B, open-label, parallel-group study of agalsidase beta in treatment-naive male pediatric patients with Fabry disease without severe symptoms (FIELD study): GL-3 clearance from kidney cells

Molecular Genetics and Metabolism, 2017

Research paper thumbnail of Response of patients with Fabry disease with the amenable GLA mutation p.N215S to treatment with migalastat

Molecular Genetics and Metabolism, 2017

Research paper thumbnail of Segregation analysis of a large LHON pedigree is consistent with the existence of a nuclear modifying gene

Research paper thumbnail of Linkage analysis of the X chromosome in a Brazilian family with Leber hereditary optic neuropathy (LHON)

Research paper thumbnail of Autosomal dominant retinitis pigmentosa: exclusion of known and mapped genes in three families